Recon: NICE Backs Revlimid for First Line Multiple Myeloma Treatment

Fundamentals of US Regulatory Affairs, 10th Edition

For 20 years, our flagship publication, Fundamentals of US Regulatory Affairs, has been giving regulatory professionals the insights and answers they need, right at their fingertips.

BUY NOW

... read more at: https://www.raps.org/news-and-articles/news-articles/2019/5/recon-nice-backs-revlimid-for-first-line-multiple